Development of albuterol sulfate pMDI using HFO-1234ze. Formulation, container closure and actuator selection considerations

Devices pMDI

resource : Poster

Development of albuterol sulfate pMDI using a low GWP propellant 1,3,3,3-Tetrafluoropropene (HFO-1234ze) to match Ventolin^® HFA inhaler. Formulation, container closure and actuator selection considerations. Presented by Ross Errington (Head of Drug Product Development) and Lei Mao (Vice Chair of IPAC-RS).

We showcased the results of this study at RDD 2025. Fill out your details below to be sent the poster.

You may also like

The transition to low GWP propellants in pMDIs – Increasing your probability of success using a collaborative approach

Development of albuterol sulfate pMDI using HFO-1234ze. Human factors engineering considerations

Mapping the product design space: Understanding and controlling manufacturing variability in pMDIs